

Product Datasheet

Respiratory Syncytial Virus Glycoprotein F Antibody (11-2-F3) [FITC] NBP2-50412F

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-50412F

Updated 1/29/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-50412F



NBP2-50412F**Respiratory Syncytial Virus Glycoprotein F Antibody (11-2-F3) [FITC]**

Product Information	
Unit Size	0.1 ml
Concentration	Please see the vial label for concentration. If unlisted please contact technical services.
Storage	Store at 4C in the dark.
Clonality	Monoclonal
Clone	11-2-F3
Preservative	0.05% Sodium Azide
Isotype	IgG1
Conjugate	FITC
Purity	Protein A purified
Buffer	PBS
Product Description	
Host	Mouse
Species	Virus
Specificity/Sensitivity	This antibody reacts with the RS virus fusion glycoprotein F (also named VP70 or F0 protein), specifically to a subunit of the F protein, F1 (also named VGP48 or 48kDa), from both subgroups A and B of RS virus. This antibody has a high neutralising activity; 90% plaque neutralization titre of 102.2 (Gimenez et al 1996). This property makes it potentially useful for the preparation of reagents for prevention and/or therapeutic use (for example, vaccines or new-generation of man-made antibodies). The characterisation of the epitope of this antibody which induce high neutralising activity will be useful for the preparation of reagents (for example vaccine) to prevent RS virus infection. A RS virus vaccine is not yet available. A vaccine could be used to increase the maternal immunity to RS virus, which would then be passed to the newborn baby to provide passive immunity. The further characterisation of the epitope recognised by this antibody, which possesses a high neutralising activity, will be useful for the preparation of reagents to prevent RS virus infection. New-generation man-made antibodies, based on the 11-2-F3 antibody, could complement the effectiveness of polivizumab (Synagis), which is used to prevent but not treat established RS virus infections (Nature Biotechnology, 2013, 31, 952).
Immunogen	Gradient-purified RSF-44 virus (subgroup A) UV inactivated for 20 minutes at 20C
Notes	This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
Product Application Details	
Applications	Western Blot, ELISA, Functional, Immunocytochemistry/ Immunofluorescence
Recommended Dilutions	Western Blot, ELISA, Immunocytochemistry/ Immunofluorescence, Functional
Application Notes	Optimal dilution of this antibody should be experimentally determined.



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-
techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-50412F

NBP1-96849	Mouse IgG1 Isotype Control (MG1) [FITC]
------------	---

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-50412F

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

